Used in pharmaceutical research as an inhibitor of the phosphoinositide 3-kinase (PI3K) enzyme, specifically the PI3Kδ isoform, which plays a key role in cell signaling pathways involved in growth, survival, and inflammation of immune cells. It is being developed for treating autoimmune disorders and chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, and interstitial lung disease due to immune dysregulation.

Inhibition of PI3Kδ reduces activation of B and T lymphocytes and production of pro-inflammatory cytokines, thereby alleviating inflammation and slowing tissue damage in target organs. This compound is under investigation to assess its efficacy and safety in humans, aiming to develop it as a specific oral therapeutic with fewer side effects compared to other agents in its class.